{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T10:49:07Z","timestamp":1648637347935},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00292-018-0534-7","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T10:26:02Z","timestamp":1540808762000},"page":"315-318","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["WHO-Klassifikation myeloischer Neoplasien"],"prefix":"10.1007","volume":"39","author":[{"given":"C.","family":"Wickenhauser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"issue":"Suppl 1","key":"534_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/annonc\/11.suppl_1.S3","volume":"11","author":"NL Harris","year":"2000","unstructured":"Harris NL, Jaffe ES, Diebold J et\u00a0al (2000) Lymphoma classification\u2014from controvery to consensus: the REAL and WHO Classification of lymphoid neoplasms. Ann Oncol 11(Suppl 1):3\u201310","journal-title":"Ann Oncol"},{"key":"534_CR2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"4","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H et al (1994) A revised european-American classification fo lymphoid neoplasms: a\u00a0proposal from the International Lymphoma Study Group. Blood 4:1361\u20131392","journal-title":"Blood"},{"key":"534_CR3","volume-title":"WHO classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"S Swerdlow","year":"2008","unstructured":"Swerdlow S, Campo E, Harris N et\u00a0al (2008) WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon"},{"key":"534_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et\u00a0al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"534_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ajh.23585","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Gisslinger H et\u00a0al (2014) Masked polycythemia vera (mPV): results of an international study. Am J Hematol 89:52\u201354","journal-title":"Am J Hematol"},{"key":"534_CR6","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"117","author":"J Thiele","year":"2011","unstructured":"Thiele J, Kvasnicka HM, M\u00fcllauer L et\u00a0al (2011) Essential thrombocythemia versus early primary myelofibrosis: a\u00a0multicenter study to validate the WHO classification. Blood 117:5710\u20135718","journal-title":"Blood"},{"key":"534_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/leu.2016.291","volume":"31","author":"H Gisslinger","year":"2017","unstructured":"Gisslinger H, Jeryczynski G, Gisslinger B et\u00a0al (2017) Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia 31:774\u2013775","journal-title":"Leukemia"},{"key":"534_CR8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/leu.2014.35","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Thiele J, Vannucchi AM et\u00a0al (2014) An overview on CALR and CSF3R mutations and a\u00a0proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 28:1407\u20131413","journal-title":"Leukemia"},{"key":"534_CR9","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","volume":"368","author":"JE Maxson","year":"2013","unstructured":"Maxson JE, Gotlib J, Pollyea DA et\u00a0al (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N\u00a0Engl J Med 368:1781\u20131790","journal-title":"N Engl J Med"},{"key":"534_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et\u00a0al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122:872\u2013884","journal-title":"Blood"},{"issue":"suppl 2","key":"534_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00277-015-2331-1","volume":"94","author":"R Hehlmann","year":"2015","unstructured":"Hehlmann R (2015) CML\u2013Where do we stand in 2015? Ann Hematol 94(suppl 2):103\u2013105","journal-title":"Ann Hematol"},{"key":"534_CR12","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.14694\/EdBook_AM.2015.35.e381","volume":"35","author":"MW Deininger","year":"2015","unstructured":"Deininger MW (2015) Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Educ Book 35:e381\u2013e388","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"534_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1182\/asheducation-2015.1.98","volume":"2015","author":"P Valent","year":"2015","unstructured":"Valent P (2015) Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. Hematology Am Soc Hematol Educ Program 2015:98\u2013105","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"534_CR14","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A et\u00a0al (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. J\u00a0Clin Oncol 31:2428\u20132436","journal-title":"J Clin Oncol"},{"key":"534_CR15","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1038\/bcj.2016.5","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Tefferi A (2016) Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer\u00a0J 6:e393","journal-title":"Blood Cancer J"},{"key":"534_CR16","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J et\u00a0al (2014) Aggerelated clonal hematopoiesis associated with adverse outcomes. N\u00a0Engl J Med 371:2488\u20132498","journal-title":"N Engl J Med"},{"key":"534_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ng.2495","volume":"45","author":"R Piazza","year":"2013","unstructured":"Piazza R, Valletta S, Winkelmann N et\u00a0al (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 45:18\u201324","journal-title":"Nat Genet"},{"key":"534_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","volume":"125","author":"CB Gambacorti-Passerini","year":"2015","unstructured":"Gambacorti-Passerini CB, Donadoni C, Parmiani A et al (2015) Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood 125:499\u2013503","journal-title":"Blood"},{"key":"534_CR19","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, T\u00fcchler H, Sol\u00e9 F et\u00a0al (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J\u00a0Clin Oncol 30:820\u2013829","journal-title":"J Clin Oncol"},{"key":"534_CR20","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L et\u00a0al (2013) Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616\u20133627","journal-title":"Blood"},{"key":"534_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V et al (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241\u2013247","journal-title":"Leukemia"},{"key":"534_CR22","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1038\/ncomms6901","volume":"6","author":"M Gerstung","year":"2015","unstructured":"Gerstung M, Pellagatti A, Malcovati L et\u00a0al (2015) Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun 6:5901","journal-title":"Nat Commun"},{"key":"534_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","volume":"126","author":"L Malcovati","year":"2015","unstructured":"Malcovati L, Karimi M, Papaemmanuil E et\u00a0al (2015) SF3B1 mutation identifies a\u00a0distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126:233\u2013241","journal-title":"Blood"},{"key":"534_CR24","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2009-01-197871","volume":"114","author":"C Haferlach","year":"2009","unstructured":"Haferlach C, Mecucci C, Schnittger S et\u00a0al (2009) AML with mutated NPM1 carrying a\u00a0normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 114:3024\u20133032","journal-title":"Blood"},{"key":"534_CR25","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1182\/blood-2013-05-503847","volume":"122","author":"RF Schlenk","year":"2013","unstructured":"Schlenk RF, Taskesen E, van Norden Y et\u00a0al (2013) The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 122:1576\u20131582","journal-title":"Blood"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-018-0534-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-018-0534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-018-0534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:35:30Z","timestamp":1572309330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-018-0534-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":25,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s00292-018-0534-7","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"29 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Wickenhauser gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}